
    
      Primary endpoint: The IV administration of MesenCure is safe under the following conditions:
      in subjects hospitalized with COVID19 moderate to severe disease, defined upon clinical
      situation and radiologic findings.

      Secondary endpoint: The IV administration of MesenCure is efficacious under the following
      conditions:

      Clinical parameters: Health questionnaire, respiratory rate, heart rate, blood pressure, RA
      O2 saturation, hospitalization duration.

      ______________________________________________________ Laboratory findings: leukocyte and
      lymphocyte count, CRP, D-Dimer, renal and liver function, optional: cytokine levels.

      ______________________________________________________ Radiologic findings: pulmonary
      infiltrates, pleural effusion.
    
  